Recipharm Secures Additional Bank Financing for Continued Growth
News Jul 14, 2015
Recipharm has entered a new five-year SEK 1 500 million term loan facility with three of the largest banks in Scandinavia, DNB, Handelsbanken and Swedbank in addition to the revolving credit facility of SEK 1 500 million arranged in September 2014. The total bank loan facilities from this group of banks then amounts to SEK 3 000 million.
The term loan facility of SEK 1 500 million will serve as an additional resource to facilitate future expansion plans set in place for the business. At the end of the first quarter 2015 Recipharm Group had cash of SEK 607 million and interest bearing debts of SEK 1 525 million.
Thomas Eldered, CEO of Recipharm AB (publ), commented: “The new financing is an important part of executing our growth strategy. This will further enhance our opportunities to continue to grow and we are continuously looking for new opportunities that can give us access to new markets, new interesting technologies and important relationships. It also enables us to keep building strong relationships with our customers throughout the pharmaceutical sector through providing them with competitive and attractive solutions.”
Setterwalls acted as legal advisor and AGL as financial advisor to Recipharm in this transaction.
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
New Bioprocessing Technique Set to Revolutionize Cell CultureNews
A technique which revolutionises cell culture by allowing the continuous production and collection of cells, has been developed by scientists at Newcastle University. The Newcastle team have developed a coating that allows individual stromal cells to “peel away” from the surface on which they are grown.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE